Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Follow-On Biologics Under Eshoo’s Bill Not A “Viable Business,” Sandoz Says

Executive Summary

No pharmaceutical company will develop follow-on biologics if anything close to the brand-friendly legislation introduced by Rep. Anna Eshoo, D-Calif., to create a regulatory pathway is passed by Congress, Sandoz Biopharmaceuticals head Hannes Teissl said
Advertisement

Related Content

Follow-on Biologics: As Mark-Ups Loom, What's Waxman's End Game?
Follow-on Biologics: As Mark-Ups Loom, What's Waxman's End Game?
Follow-On Grudge Match: The Round One Scorecard In Waxman vs. Eshoo
Biosimilar Interchangeability Does Not Create Substitution Under House Bills
BIO Wants 14 Years Of Data Exclusivity For Biosimilars; Will Waxman Buy It?
Sandoz Branding Itself As Generics Shop With Hard-To-Manufacture Products
Sandoz Branding Itself As Generics Shop With Hard-To-Manufacture Products

Topics

Advertisement
UsernamePublicRestriction

Register

PS050879

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel